26 reports

  • May 12, 2017: Otonomy Announces OTIPRIO Data Presentation and Symposium at the American Society of Pediatric Otolaryngology Annual Meeting
  • May 12, 2017: Otonomy Announces OTIPRIO Data Presentation and Symposium at the American Society of Pediatric Otolaryngology Annual Meeting

Summary Otonomy Inc (Otonomy) develops and markets treatments for diseases and disorders of the ear.The company’s Otiprio is the US FDA approved ciprofloxacin otic suspension indicated during tympanostomy tube placement surgery in pediatric patients. Its pipeline portfolio encompasses Otividex for the treatment of...

  • Ear, Nose, And Throat Medicine
  • United States
  • Company
  • Company Financials
  • Otonomy, Inc.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • Molecular Diagnostic
  • Therapy
  • Sensorion S.A.
  • APR 23, 2018: FIRST POTENTIAL BIOMARKER FOR NOISE-INDUCED HEARING LOSS IDENTIFIED
  • Phase II - Trial Details

The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ## and ## respectively.

  • Ear, Nose, And Throat Medicine
  • Molecular Diagnostic
  • World
  • Product Initiative
  • Sensorion S.A.
  • Sep 24, 2015: Otonomy to Present Results for OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting
  • Jun 20, 2017: Otonomy to Host Key Opinion Leader Meeting for Investors on Meniere's Disease

Following the lead-in period, eligible subjects will be randomized ##:## to a single intratympanic injection of ## mg OTO-## or placebo (gel vehicle).

  • Ear, Nose, And Throat Medicine
  • Pharmaceutical
  • United States
  • Product Initiative
  • Otonomy, Inc.
  • Sep 24, 2015: Otonomy to Present Results for OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting
  • from baseline to Month 3 in the OTIVIDEX group vs. 40% for placebo.

Following an initial one month lead-in period, eligible subjects were randomized ##:## to a single intratympanic injection of OTIVIDEX or placebo.

  • Ear, Nose, And Throat Medicine
  • Pharmaceutical
  • United States
  • Product Initiative
  • Otonomy, Inc.
  • Dec 28, 2017: Auris Medical to Provide Update on Its AM-111 Hearing Loss Program on Thursday, January 4, 2018
  • OTHER LOCATIONS & SUBSIDIARIES

The securities are being offered in a unit comprised of one share, one Series A warrant to purchase ##. ## of a share and one Series B warrant to purchase ##. ## of a share.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • United States
  • Company Financials
  • Auris Medical Holding AG

According to the American Academy of Otolaryngology, the total cost of a cochlear implant, including everything from evaluation to rehabilitation, can be as much as $##, ##.

  • Ear, Nose, And Throat Medicine
  • World
  • Carl Zeiss AG
  • Danaher Corporation
  • Olympus Corporation

ACCORDING TO THE AMERICAN ACADEMY OF OTOLARYNGOLOGY, THE TOTAL COST OF A COCHLEAR IMPLANT, INCLUDING EVERYTHING FROM EVALUATION TO REHABILITATION CAN COST AS MUCH AS $##, ##.

  • Ear, Nose, And Throat Medicine
  • World
  • Medtronic, Inc.
  • Olympus Corporation
  • Smith & Nephew Plc
  • Aug 03, 2017: Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate Update
  • May 09, 2018: Otonomy Reports First Quarter 2018 Financial Results and Provides Corporate Update

Lambert, M. D., Professor and Chair, Department of Otolaryngology-Head & Neck Surgery, Medical University of South Carolina, and Anthony A.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • United States
  • Company Financials
  • Otonomy, Inc.

Audigy is a preeminent US based provider of business and performance management solutions to independent hearing care, otolaryngology, otology and neurotology practices and leading University programs in North America.

  • Ear, Nose, And Throat Medicine
  • World
  • Demand
  • Cochlear Limited
  • Sonova Holding AG
  • May 04, 2015: Auris Medical Provides Update on Clinical Development Plan for AM-111

The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Ear, Nose, And Throat Medicine
  • United States
  • World
  • Product Initiative
  • Auris Medical Holding AG

You can easily book an appointment with one online.

  • Ear, Nose, And Throat Medicine
  • World
  • Forecast
  • Natus Medical Incorporated
  • William Demant
  • 5.2.3 BY REGION
  • is enabling people to purchase the technologically

The ENT devices market is poised to reach USD 14,001.3 million by 2020 from USD 10,219.3 million in 2015, growing at a CAGR of 6.5% from 2015 to 2020. This market is categorized on the basis of products, end users, and regions. Major factors contributing to the growth of the global ENT devices market include high prevalence...

  • Ear, Nose, And Throat Medicine
  • North America
  • United States
  • World
  • Market Size
  • PATHWAY WITH THE FDA AND EMA IN THE SECOND QUARTER OF 2018. THE DATA WILL ALSO BE SUBMITTED FOR PEER REVIEW PUBLICATION AND PRESENTATION AT A MEDICAL MEETING IN 2018.
  • Nov 28, 2017: Auris Medical Reports Top-Line Results from Phase 3 Trial of AM-111 in Sudden Deafness

Patients were randomized to receive AM- ## ##. ## mg/ mL, ##. ## mg/ mL or placebo in a ##:##:## ratio.

  • Ear, Nose, And Throat Medicine
  • Health Services
  • Hospital
  • United States
  • Product Initiative
  • Apr 12, 2018: Sensorion reports full year 2017 results
  • Apr 12, 2018: Sensorion reports full year 2017 results

More than one third of all adults suffer from one form or another of vestibular disorders.

  • Ear, Nose, And Throat Medicine
  • Healthcare
  • Pharmaceutical
  • France
  • Sensorion S.A.
  • Mar 04, 2011: Auris Medical's AM-111 Protects Against Hearing Loss From Cochlear Implant Electrode Insertion Trauma
  • Nov 28, 2017: Auris Medical Reports Top-Line Results from Phase 3 Trial of AM-111 in Sudden Deafness

Patients were randomized to receive AM- ## ##. ## mg/ mL, ##. ## mg/ mL or placebo in a ##:##:## ratio.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • Therapy
  • United States
  • Product Initiative
  • 8.4.3 RECENT DEVELOPMENTS

Audigy is a preeminent US based provider of business and performance management solutions to independent hearing care, otolaryngology, otology and neurotology practices and leading University programs in North America.

  • Ear, Nose, And Throat Medicine
  • World
  • Cochlear Limited
  • RION Co., Ltd
  • Sonova Holding AG
  • 5. All the trials included are unique trials.

Boehringer Sohn AG & Co KG ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## Astellas Pharma Inc ## ## ## ## ## ## ## E.

  • Cancer
  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • World
  • Bristol-Myers Squibb Company
  • 4.1 BIBLIOGRAPHY

ET AL. (2011) ' HEAD AND NECK CANCER-PART ##: EPIDEMIOLOGY, PRESENTATION, AND PRESERVATION', CLINICAL OTOLARYNGOLOGY, ##(##), PP. ##-##.

  • Cancer
  • Ear, Nose, And Throat Medicine
  • Japan
  • United States
  • Forecast
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • Oncology
  • United States
  • World
  • Apr 20, 2012
  • FEATURED NEWS & PRESS RELEASES

KG ## ## ## ## ## ## Orbis Biosciences, Inc. ## ## ## ## ## ## Otologic Pharmaceutics, Inc. ## ## ## ## ## ## Xigen SA ## ## ## ## ## ## Total ## ## ## ## ## ## Source: Global Markets Direct Company Name Phase III Phase II Phase I

  • Ear, Nose, And Throat Medicine
  • United States
  • World
  • Company Operations
  • Product Initiative

Sikora, M. D., Associate Professor of Otolaryngology and Co-Director of the Head and Neck Cancer Program in the NCI Comprehensive-Designated Dan L.

  • Ear, Nose, And Throat Medicine
  • Sexually Transmitted Disease
  • Vaccine
  • United States
  • Advaxis, Inc.
  • 9.2 References

American Academy of Otolaryngology.

  • Ear, Nose, And Throat Medicine
  • Health Services
  • Healthcare
  • Therapy
  • World
  • Clinical Trial Profile Snapshots

Sikora, M. D., Associate Professor of Otolaryngology and co-director of the Head and Neck Cancer Program in the NCI Comprehensive-Designated Dan L.

  • Clinical Trial
  • Drug Discovery And Development
  • Ear, Nose, And Throat Medicine
  • World
  • Product Initiative

Head and neck cancer

4385 5000 3900
  • Epidemiologist Insight

Otolaryngology - Head and Neck Surgery, ##(##), ##-## < DOI> ##. ##/ j. otohns. 2006. ##. ##< / DOI>. de Souza DLB, Bernal Pérez MM, Curado MP (2011) Predicted incidence of oral cavity, oropharyngeal, laryngeal, and hypopharyngeal cancer in Spain and implications for cance

  • Ear, Nose, And Throat Medicine
  • United States
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
  • is a representative pipeline of the nanoparticles under review in research
  • NANOPARTICLES FOR INNER EAR DISEASES: RESEARCH PIPELINE AT UNIVERSITIES

INTRODUCTION A significant proportion of the world’s population is suffering from otologic diseases. Absence of any disease modifying drugs is a big unmet need in the market. The current treatment of inner ear diseases is primarily based on counselling, electric and magnetic nerve stimulations. At the same time, there is a growing...

  • Ear, Nose, And Throat Medicine
  • United States
  • AudioCure Pharma GmbH
  • Autifony Therapeutics Limited
  • Cochlear Limited